Following primary infection with Herpes Simplex Virus (HSV), the virus persists in episomal form in the local sensory ganglia. Periodic reactivation by various stimuli results in a recrudescent lesion at or near the initial site of infection due to retrograde axonal transport [l] . As yet there is no suitable vaccine for its prevention within the human population p].
We investigated the potential of a large number of commercial and experimental adjuvant preparations to promote a protective immune response using an HSV-1 glycoprotein subunit vaccine. The various formulations induced markedly different degrees of protection and humoral immune responses, with no correlation between these parameters. We are currently assessing the cellular immune responses generated by the same group of adjuvants and will attempt to correlate these with protection.
The results emphasise the requirement of adjuvants when using subunit preparations as vaccine formulations and demonstrate that the magnitude and effectiveness of the induced immune response varies greatly with the choice of adjuvant. Subunit antigen was prepared by propagation of HSV-1 (F strain) in Vero cells followed by subsequent detergent extraction as previously described 131. Adjuvant preparations used were MPL i TDM (Sigma, Poole, Dorset), Following the administration of 10 LD50 HSV-1 (WAL), mice were observed for subsequent death over a 21 day period. A broad range of protection levels, ranging from One of the primary uses of adjuvant in the laboratory is the production of immune sera, CompIete Freund's adjuvant (CFA) being the routine choice [S]. From our results it can be seen that many commercially available formulations are significantly better at inducing an immune response, even after one dose, without associated side effects [6].
Our results also illustrate the increased efficacy of many formulations over alum associated antigen in producing a protective response. As alum is the only adjuvant preparation licenced for use in humans m, more research is needed to determine toxicity and efficacy of new and novel formulations with a view to their utilisation within the human population. 
